{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:04:37Z","timestamp":1773299077093,"version":"3.50.1"},"reference-count":13,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,6,18]],"date-time":"2010-06-18T00:00:00Z","timestamp":1276819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJOG"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:p> <jats:italic>Please cite this paper as:<\/jats:italic> von Hertzen H, Huong N, Piaggio G, Bayalag M, Cabezas E, Fang A, Gemzell\u2010Danielsson K, Hinh N, Mittal S, Ng E, Chaturachinda K, Pinter B, Puscasiu L, Savardekar L, Shenoy S, Khomassuridge A, Tuyet H, Velasco A, Peregoudov A, for the WHO Research Group on Postovulatory Methods of Fertility Regulation. Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial. BJOG 2010;117:1186\u20131196.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> To compare 400 and 800\u2003\u03bcg sublingual or vaginal misoprostol 24\u2003hours after 200\u2003mg mifepristone for noninferiority regarding efficacy in achieving complete abortion for pregnancy termination up to 63\u2003days of gestation.<\/jats:p><jats:p><jats:bold>Design\u2002<\/jats:bold> Placebo\u2010controlled, randomised, noninferiority factorial trial, stratified by centre and length of gestation. Misoprostol 400 or 800\u2003\u03bcg, administered either sublingually or vaginally, with follow up after 2 and 6\u2003weeks.<\/jats:p><jats:p><jats:bold>Setting\u2002<\/jats:bold> Fifteen obstetrics\/gynaecology departments in ten countries.<\/jats:p><jats:p><jats:bold>Population\u2002<\/jats:bold> Pregnant women (<jats:italic>n<\/jats:italic>\u2003=\u20033005) up to 63\u2003days of gestation requesting medical abortion.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Two\u2010sided 95% CI for differences in failure of complete abortion and continuing pregnancy, with a 3% noninferiority margin, were calculated. Proportions of women with adverse effects were recorded.<\/jats:p><jats:p><jats:bold>Outcome measures\u2002<\/jats:bold> Complete abortion without surgical intervention (main); continuing live pregnancies, induction\u2010to\u2010abortion interval, adverse effects, women\u2019s perceptions (secondary).<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Efficacy outcomes analysed for 2962 women (98.6%): 90.5% had complete abortion after 400\u2003\u03bcg misoprostol, 94.2% after 800\u2003\u03bcg. Noninferiority of 400\u2003\u03bcg misoprostol was not demonstrated for failure of complete abortion (difference: 3.7%; 95% CI 1.8\u20135.6%). The 400\u2010\u03bcg dose showed higher risk of incomplete abortion (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01) and continuing pregnancy (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01) than 800\u2003\u03bcg. Vaginal and sublingual routes had similar risks of failure to achieve complete abortion (<jats:italic>P<\/jats:italic>\u2003=\u20030.47, difference in sublingual minus vaginal \u22120.7%, 95% CI \u22122.6\u20131.2%). A similar pattern was observed for continuing pregnancies (<jats:italic>P<\/jats:italic>\u2003=\u20030.21). Fewer women reported adverse effects with vaginal than sublingual administration and with the 400\u2010\u03bcg dose than the 800\u2010\u03bcg dose. Of the women, 94% were satisfied or highly satisfied with the regimens, 53% preferred the sublingual route and 47% preferred the vaginal route.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> A 400\u2010\u03bcg dose of misoprostol should not replace the 800\u2010\u03bcg dose when administered 24\u2003hours after 200\u2003mg mifepristone for inducing abortion in pregnancies up to 63\u2003days. Sublingual and vaginal misoprostol have similar efficacy, but vaginal administration is associated with a lower frequency of adverse effects.<\/jats:p>","DOI":"10.1111\/j.1471-0528.2010.02636.x","type":"journal-article","created":{"date-parts":[[2010,6,18]],"date-time":"2010-06-18T09:44:00Z","timestamp":1276854240000},"page":"1186-1196","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial"],"prefix":"10.1111","volume":"117","author":[{"given":"H","family":"von Hertzen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NTM","family":"Huong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Piaggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Bayalag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Cabezas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AH","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Gemzell\u2010Danielsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ND","family":"Hinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EHY","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Chaturachinda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Puscasiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Savardekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Khomassuridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HTD","family":"Tuyet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Peregoudov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the WHO Research Group on Postovulatory Methods of Fertility Regulation","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,8,16]]},"reference":[{"key":"e_1_2_11_2_2","volume-title":"Safe Abortion: Technical And Policy Guidance For Health Systems","author":"World Health Organization (WHO)","year":"2003"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2000.tb13273.x"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504133321502"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deg475"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31818d8eb4"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2003.07.004"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2008.09.001"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2008.02034.x"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4755-5-2"},{"key":"e_1_2_11_11_2","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1471-0528.2003.02430.x","article-title":"WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: Efficacy","volume":"110","author":"von Hertzen H","year":"2003","journal-title":"BJOG"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809146"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60914-3"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh005"}],"container-title":["BJOG: An International Journal of Obstetrics &amp; Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1471-0528.2010.02636.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1471-0528.2010.02636.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T19:57:16Z","timestamp":1698782236000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/j.1471-0528.2010.02636.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,16]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1111\/j.1471-0528.2010.02636.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1471-0528.2010.02636.x","archive":["Portico"],"relation":{},"ISSN":["1470-0328","1471-0528"],"issn-type":[{"value":"1470-0328","type":"print"},{"value":"1471-0528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,16]]},"assertion":[{"value":"2010-08-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}